PXL 01

Drug Profile

PXL 01

Alternative Names: PXL-01

Latest Information Update: 04 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmaSurgics
  • Developer PharmaSurgics; ProMore Pharma; Technomark Life Sciences
  • Class Glycoproteins; Peptides
  • Mechanism of Action Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Interleukin 8 inhibitors; Plasminogen activator inhibitor-1 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Post-surgical adhesions

Highest Development Phases

  • Phase III Post-surgical adhesions

Most Recent Events

  • 03 Sep 2018 Phase-III clinical trials in Post-surgical adhesions (Prevention) in Canada, USA, North America, India, Poland, Germany and Sweden (SC) (ProMore Pharma website, September 2018)
  • 03 Sep 2018 Promore Pharma plans a phase I/II trial for Scars (Prevention) in Sweden
  • 14 Aug 2018 Promore Pharma plans a phase III trial for patients with flexor Tendon injuries in the hand
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top